Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benecol, Take Control Marketing Highlight Approved CHD Health Claims

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare's Benecol spread will soon be carrying labeling stating it can reduce the risk of coronary heart disease, the company said. The new labeling follows FDA's Sept. 8 approval of McNeil's health claim petition.

You may also be interested in...



Mars CocoaVia Chocolate Bars Receive No Kudos In FDA Warning Letter

CocoaVia chocolate bars are adulterated "in that they contain a food additive, namely folic acid, which is unsafe within the meaning of section 409" of the FD&C Act, CFSAN Office of Compliance Director Joseph Baca tells Mars in a recent warning letter

Mars CocoaVia Chocolate Bars Receive No Kudos In FDA Warning Letter

CocoaVia chocolate bars are adulterated "in that they contain a food additive, namely folic acid, which is unsafe within the meaning of section 409" of the FD&C Act, CFSAN Office of Compliance Director Joseph Baca tells Mars in a recent warning letter

Mars CocoaVia Chocolate Bars Receive No Kudos In FDA Warning Letter

CocoaVia chocolate bars are adulterated "in that they contain a food additive, namely folic acid, which is unsafe within the meaning of section 409" of the FD&C Act, CFSAN Office of Compliance Director Joseph Baca tells Mars in a recent warning letter

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel